Navigation Links
Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Date:1/8/2008

BOSTON, Jan. 8 /PRNewswire/ -- Surface Logix today announced positive results in the Company's Phase 2a clinical trial of SLx-2101 in hypertension. The randomized, double-blind, placebo-controlled crossover Phase 2a study in 60 patients with uncontrolled hypertension demonstrated that SLx-2101 caused clinically significant reductions in blood pressure and was well tolerated. The trial was designed to examine the safety, tolerability and effect on blood pressure in patients of repeat oral doses of SLx-2101 once daily for up to 14 days.

"These data confirm the promise of efficacy seen in earlier clinical trials, and we plan to initiate a Phase 2b study of SLx-2101 in hypertension in the third quarter of 2008," said Jim Mahoney, President and CEO of Surface Logix. "We believe that with our demonstrated 24-hour coverage from once daily dosing and excellent tolerability profile, we will be able to uniquely position SLx-2101 in several segments of the hypertension market."

SLx-2101 is an oral, potent, selective, fast-onset, long-acting PDE5 inhibitor. Other PDE5 inhibitors have traditionally been used to treat erectile dysfunction (ED). SLx-2101 was designed specifically to expand the therapeutic potential of PDE5 inhibition beyond ED into larger cardiovascular markets such as hypertension. SLx-2101 is uniquely positioned among the known PDE5 inhibitors to address cardiovascular disease because, compared to currently marketed PDE5 drugs, SLx-2101 preferentially distributes into cardiovascular tissue. With its large volume of distribution, SLx-2101 achieves sustained plasma levels and a long duration of action, without showing accumulation upon repeat dosing. This allows for daily or on demand dosing with a predictable response in a number of cardiovascular disorders that currently marketed PDE5 therapies cannot adequately address.

"To achieve efficacy in cardiovascular disease, your compound has to get into the right tissues," commented Dr. Pau
'/>"/>

SOURCE Surface Logix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Surface Logix, Inc. to Present at the Piper Jaffray Health Care Conference
2. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
3. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
6. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
7. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
8. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
11. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... BERKELEY, Calif. and ... CMC Biologics, Inc. , a global leader in ... therapeutic proteins, announced today that, as part of its ... expansion of its North American manufacturing facility in ... a single-use Bioreactor 6Pack™ facility.  The Bioreactor 6Pack™ configuration ...
(Date:6/30/2015)... ATLANTA , June 30, 2015 Legal-Bay ... the first bellwether trial in the multidistrict litigation (MDL) ... scheduled to begin October 13 th , 2015. There ... Inc. which have been consolidated before a federal judge ... that the first bellwether trial will begin in October ...
(Date:6/29/2015)... BANGALORE , June 30, 2015 ... segmented by Primary Packaging Material (Plastic, Glass, Paper, Metal) ... IV Bags, Mini-jars, Pouches, Syringes, Tubes, Vials, Sachets) - By ... Europe , Asia Pacific , ... and Africa ) - discussing Industry ...
Breaking Medicine Technology:CMC Biologics Expands GMP Manufacturing Capacity in the United States 2CMC Biologics Expands GMP Manufacturing Capacity in the United States 3Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 2Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 3Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 2Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 3
... Technologies, Inc. was honored with the Belfast Ambassador Award ... Stormont, Belfast. The award was presented to the company by ... developing areas of Belfast, Ireland. HeartSine CEO ... in Stormont on behalf of HeartSine, said, "We are honored ...
... revised Concepts in Clinical Pharmacokinetics , a web-based ... Georgia. Developed in cooperation with the American Society of ... Continuing Education and College of Pharmacy, the new Online ... fundamental principles of absorption, distribution, metabolism, and the elimination ...
Cached Medicine Technology:HeartSine Technologies Honored With Belfast Ambassador Award at Belfast Business Top 50 Event 2Newly Revised Concepts in Clinical Pharmacokinetics Web-Based Continuing Education Course Offered by the University of Georgia 2Newly Revised Concepts in Clinical Pharmacokinetics Web-Based Continuing Education Course Offered by the University of Georgia 3
(Date:6/30/2015)... New York (PRWEB) , ... June 30, 2015 ... ... ( http://www.xareltolawsuit2015.com/ ) currently pending in a federal multidistrict litigation now underway in ... Court convenes its next monthly Status Conference. According to the Court’s calendar, that ...
(Date:6/30/2015)... NJ (PRWEB) , ... June 30, 2015 , ... Dr. ... primary care sports medicine physician. He specializes in the diagnosis and treatment of non-surgical ... and for the people who participate in recreational athletics and use exercise to stay ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates today ... Healthcare Research & Analytics , a consultative healthcare market research practice that is ... businesses. HRA offers quantitative and qualitative, custom and multi-client primary market research services ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... partnering to improve access to cancer prevention, screening and care for the people ... announced an affiliation that will see Roswell Park faculty providing clinical consultations to ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... New Energy ... York July 7th and 11th 2015. Timber frame post and beam raisings offer a ... , “Raising a timber frame is an important and exciting event – ...
Breaking Medicine News(10 mins):Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 4Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 5Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 2Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 3Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 4
... French . , MONTREAL, December 14, 2010 The first ... to recognize the sound of their parents, voice and the parents ... and newborns admitted to the intensive care unit can be very ... Jan Lariviere, a nurse in the neonatal clinic and the Neonatal ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Most ... United States is funded by states, not the federal government, ... variation in the extent to which states prioritized human embryonic ... in states could likely have been funded under federal government ...
... a woman in New Hampshire have received the first kidney ... Organ Procurement and Transplantation Network (OPTN) that uses a Carnegie ... donors. Both recipients Ken Crowder of St. Louis and ... were willing to donate a kidney but who were medically ...
... (HealthDay News) -- A federal judge ruled Monday that the ... government has no authority to require citizens to buy health ... new legislation, signed into law in March by President Barack ... supporters and opponents of the legislation anticipate the validity of ...
... that alter the activity of genes direct changes to ... control when genes are switched on and off, called epigenetic ... an opening for the cancerous growth of cells. Researchers ... at work on a genome-wide scale in cases of ovarian ...
... HealthDay Reporter , MONDAY, Dec. 13 (HealthDay News) ... may be child,s play, researchers report. A new ... cereals if they,re given a selection of choices at breakfast, ... fruit instead. The 5-to-12-year-olds in the study still ate ...
Cached Medicine News:Health News:Once upon a time in the Intensive Care Unit ... 2Health News:States Now Fund Most Embryonic Stem Cell Research in U.S. 2Health News:2 people receive kidney transplants in pilot program using CMU software 2Health News:2 people receive kidney transplants in pilot program using CMU software 3Health News:Federal Judge Strikes Down Health Reform Law 2Health News:Federal Judge Strikes Down Health Reform Law 3Health News:Ovarian cancer advances when genes are silenced 2Health News:Kids Not So Stuck on Sugary Breakfast Cereals, Study Finds 2Health News:Kids Not So Stuck on Sugary Breakfast Cereals, Study Finds 3
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
... contains 266 amino acids and is variably N-glycosylated. ... estimates of between 43 and 56 kDa. Insulin-like ... with high affinity but do not bind insulin. ... characterized at this time, IGFBP-3 has been shown ...
... detection and semi-quantitation of ... antigen in serum as ... diagnosis of autoimmune disease. ... performed either manually or ...
Qualitative EIA for SS-A, SS-B, Sm, Sm/RNP plus Scl-70 and Jo-1...
Medicine Products: